Abstract
The presence of unique heavy chain-only antibodies (HCAbs) in camelids was discovered at Vrije Universiteit Brussel (VUB, Brussels, Belgium) at a time when many researchers were exploring the cloning and expression of smaller antigen-binding fragments (Fv and Fab) from hybridoma-derived antibodies. The potential importance of this discovery was anticipated, and efforts were immediately undertaken to understand the emergence and ontogeny of these HCAbs as well as to investigate the applications of the single-domain antigen-binding variable domains of HCAbs (nanobodies). Nanobodies were demonstrated to possess multiple biochemical and biophysical advantages over other antigen-binding antibody fragments and alternative scaffolds. Today, nanobodies have a significant and growing impact on research, biotechnology, and medicine.
Original language | English |
---|---|
Pages (from-to) | 3-17 |
Number of pages | 15 |
Journal | Methods in Molecular Biology: Experimental Cholestasis Research |
Volume | 2446 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.Keywords
- Animals
- Antibodies/chemistry
- Biotechnology
- Camelids, New World
- Immunoglobulin Heavy Chains
- Single-Domain Antibodies/chemistry